Why the study?
Do screening, monitoring, and treatment strategies improve clinical outcomes in adults with CKD stages 1 to 3?
Do screening, monitoring, and treatment strategies improve clinical outcomes in adults with CKD stages 1 to 3?
Evidence supports the use of ACE inhibitors and ARBs to reduce end-stage renal disease in CKD patients with diabetes and macroalbuminuria, though the benefits of screening and monitoring remain uncertain.
No takes yet. Share an insight, caveat, or question.
ACE inhibitors and ARBs reduce ESRD in diabetic macroalbuminuria; confirms efficacy and supports targeted use in CKD stages 1-3.
Howard A Fink (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: